Therefore, these results are not directly comparable to our study.19 In another multicenter study involving partial or total gastrectomy specimens from 212 patients, the incidence of HER2 was determined to be 16.5% (35/212).20 In a single-center study involving 135 patients, it was observed that HER-2 positive patients were similar to negative patients concerning age, gender, tumor size, tumor location, tumor T stage, lymph node metastasis, histological type, differentiation, lymphovascular invasion, perinodal, perineural invasion, and stage.21 This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.